Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | melanoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). | 29973670 |
PubMed Id | Reference Title | Details |
---|---|---|
(29973670) | Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. | Full reference... |